Redhill Biopharma Ltd
Research Redhill Biopharma Ltd (RDHL) on Bullrun: market cap USD 4.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRDHL
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 4.47M
- Financial periodQ4 2025
- RevenueUSD 286.00K
- Net income-USD 429.00K
- Free cash flow-USD 9.66M
Valuation Snapshot
latest market cap is USD 4.47M.
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection;
Frequently asked questions
What is Redhill Biopharma Ltd's market cap?
Redhill Biopharma Ltd's market capitalization is USD 4.47M.
What does Redhill Biopharma Ltd do?
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.